RAPP Rapport Corp: Year-over-year earnings per share growth for the last twelve months

Official company branding of Rapport Therapeutics (RAPP)

Rapport Therapeutics, Inc. (RAPP) is investing billions into the development of precision neurobiological drugs. Quarterly earnings per share growth illustrates the adaptation of these investments, where -19.00 determines this parameter level. A secure Western legal status protects the company from sanctions, while the RAP platform enables the effective treatment of depression and epilepsy, minimizing harmful side effects for patients.

Rapport Therapeutics (RAPP) Earnings per share growth in annualized terms for the last twelve months: for the period 06/08/2024 - 11/16/2026

Analytical breakdowns for Rapport Therapeutics, Inc.

- share price and consensus valuation forecast:
Fundamental company analysis:rapportrx.com, RAPP
Manufactured product of Rapport Corp

Quarterly EPS growth measures the dynamics of net income per share, determining the efficiency of business capitalization. This metric captures the percentage change in earnings, allowing investors to assess a company's resilience to market shocks. By analyzing the quarterly EPS change, one can identify the risk of overpayment or the potential undervaluation of an asset. For Rapport Therapeutics, Inc. (RAPP), this indicator reflects the cost of intensive R&D expenditures required to attract elite neurobiologists. High research and development budgets directly impact the final profitability of each share.

Analysis of competing companies

JAZZ (Jazz Pharmaceuticals PLC) - Year-over-year net earnings per share growth for the last 12 months|Cytokinetics Corp (CYTK) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months PTC Therapeutics, Inc.|SRRK: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Centessa Corp (CNTA)|Year-over-year earnings per share growth for the last twelve months DYN (Dyne Therapeutics Inc)|Year-over-year earnings per share growth for the last twelve months Edgewise Pharma EWTX|Alumis Pharma - Year-over-year earnings per share growth for the last twelve months|ZVRA - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Contineum Therapeutics, Inc.|LRMR: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Capricor Therapeutics CAPR|Year-over-year net earnings per share growth for the last 12 months TRDA|Earnings per share growth in annualized terms for the last twelve months Channel PTHS|Year-over-year earnings per share growth for the last twelve months MediciNova Inc. (MNOV)|SER - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth BTAI (BioXcel Therapeutics Inc)|ProMIS Neurosciences (PMN) - Earnings per share growth in annualized terms for the last twelve months|Apimeds Pharmaceuticals, Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months AEON Biopharma, Inc.|NLSP (NLS Pharma) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last 12 months BNOX|Year-over-year earnings per share growth for the last twelve months FSD Pharma|Quarterly EPS earnings growth Reata